tetano
Editor, Senior Moderator
Mol Ther. 2013 Jul 8. doi: 10.1038/mt.2013.162. [Epub ahead of print]
Co-administration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell mediated responses.
Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC.
Source
The Jenner Institute, University of Oxford, Oxford, UK.
Abstract
Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccineMVA-NP+M1 is able to boost memory T cell responses in adultsaged 50-85 years. Pre-clinical studies have demonstrated that viral vectored vaccines can act as adjuvants when co-administered with protein-based vaccines.We have conducted a phase I clinical trial to compare co-administration of seasonal influenza vaccine and MVA-NP+M1, to seasonal influenza vaccine alone in adults aged 50 years and over. This combination of vaccines was safe and well tolerated. T cell responses to internal influenza proteins were boosted to significantly higher levels in the group receiving MVA-NP+M1 compared to the group receiving seasonal influenza vaccine alone. Rates of seroprotection and seroconversionagainst the three vaccine strains were similar in both groups however there was a significant increase in the geometric mean titre ratio for the H3N2 component of seasonal influenza vaccine in the co-administration group. While some vaccine combinations result in immune interference, the co-administration of MVA-NP+M1 alongside seasonal influenza vaccine is shown here to increase some influenza strain-specific antibody responses and boost memory T cells capable of recognising a range of influenza A subtypes.Molecular Therapy (2013); doi:10.1038/mt.2013.162.
PMID:
23831594
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23831594
Co-administration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell mediated responses.
Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC.
Source
The Jenner Institute, University of Oxford, Oxford, UK.
Abstract
Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccineMVA-NP+M1 is able to boost memory T cell responses in adultsaged 50-85 years. Pre-clinical studies have demonstrated that viral vectored vaccines can act as adjuvants when co-administered with protein-based vaccines.We have conducted a phase I clinical trial to compare co-administration of seasonal influenza vaccine and MVA-NP+M1, to seasonal influenza vaccine alone in adults aged 50 years and over. This combination of vaccines was safe and well tolerated. T cell responses to internal influenza proteins were boosted to significantly higher levels in the group receiving MVA-NP+M1 compared to the group receiving seasonal influenza vaccine alone. Rates of seroprotection and seroconversionagainst the three vaccine strains were similar in both groups however there was a significant increase in the geometric mean titre ratio for the H3N2 component of seasonal influenza vaccine in the co-administration group. While some vaccine combinations result in immune interference, the co-administration of MVA-NP+M1 alongside seasonal influenza vaccine is shown here to increase some influenza strain-specific antibody responses and boost memory T cells capable of recognising a range of influenza A subtypes.Molecular Therapy (2013); doi:10.1038/mt.2013.162.
PMID:
23831594
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23831594